Topic

Articles

The register supports cross-functional teams of chemists and biologists in developing non-natural, chemically-modified therapeutics for drug discovery.

Dotmatics Launches Bioregister 2020.1

In the study, GigaGen presents a novel technology for producing a new class of drug, recombinant hyperimmunes, that may potentially generate new COVID-19 therapies.

GigaGen Highlights Research Describing New Class of Drugs for Potential COVID-19 Therapy

Jane E. Remillard is the leader of the Life Sciences Intellectual Property Team at Nelson Mullins, jane.remillard@nelsonmullins.com

Jill Gorny Sloper is a partner at Nelson Mullins with a focus on patent law in the biotechnology, pharmaceutical, and life science fields, jill.sloper@nelsonmullins.com

Stringent patentability requirements present a challenge to obtaining broad-based antibody claims, so companies should develop a strategy based on multiple reinforcing layers of protection. 

Patentability Considerations for Antibody-Related Inventions

FDA’s EUA provides the first new treatment for COVID-19 patients with severe symptoms.

Remdesivir Approved for Emergency Use

Eurofins DiscoverX partners with VelaLabs to enable VelaLabs to perform highly reproducible potency lot release assays under GLP/GMP conditions.

Eurofins DiscoverX Grants Bioassay Certification to VelaLabs

Under the agreement, ERS Genomics will license its gene-editing technology to Aelian Biotechnoloy to support its commercial functional genomic screening platform.

ERS Genomics, Aelian Biotechnology in CRISPR/Cas9 License Agreement

ERS Genomics revealed that the European Patent Office (EPO) has rejected arguments filed in opposition to patent EP2800811, which is directed to the single-guide CRISPR/Cas9 gene editing system and covers uses in cellular and non-cellular settings.


EPO Confirms Novelty of CRISPR/Cas9 Gene Editing System Patent

Inflazome, a biotech company based in Dublin, Ireland, has announced that the United States Patent and Trademark Office (USPTO) and the European Patent Office (EPO) will grant its patent applications in January 2020.


Inflazome to be Granted Patents in US and Europe

Agnes Shanley is senior editor of Pharmaceutical Technology.

As the high cost of drugs continues to erode public opinion, experts ask whether price controls are the best, or only, way to improve
access to medicines and regain the public’s trust.


Public Opinion: Can Pharma Chart a New Course?

Swiss-based specialist pharma R&D company, MetP Pharma, has been granted a Notice of Allowance from the Unites States Patent and Trademark Office (USPTO) for its patent titled, “Treatment of Demyelineating Diseases.”


Intellectual Property & Patents